Remdesivir becomes first anti-COVID-19 drug recommended by EU
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The European MedicinesAdministration's EMA Human Drug Council (CHMP) supports the use of Gilead's Remdesivir for the treatment of patients with pneumonia with a new coronavirusCOVID-19infected within GileadThe move makes Remdesivir the first anti-COVID-19 drug to be approved by the European Unionthe recommendation is based on data from the NIAID-ACTT-11 study of the National Institute of Allergy and Infectious Diseases (NIAID), which found that patients treated with Remdesivir recovered about 11 days later and given a placebo for 15 daysbut the agency stressed that no efficacy was observed in mild to moderate patients: both the Remdesivir group and the placebo group recovered for five daysFor patients with severe illness (about 90 percent of the study population), the recovery time was 12 days for the Redseve group and 18 days for the placebo grouptaking into account the available data, CHMP believes that patients with pneumonia who need oxygen supplements can benefit from Remdesivir's treatment, i.epatients with severe COVID-19
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
